-
公开(公告)号：EP3235819A1
公开(公告)日：2017-10-25
申请号：EP15869312.7
申请日：2015-12-15
申请人： Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
摘要： The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
摘要翻译： 本申请涉及药物化学领域，特别涉及通式（I）所示的吡咯并嘧啶化合物，其立体异构体或其药学上可接受的盐。 本发明还涉及通式（I）代表的吡咯并嘧啶化合物的制备方法，药物组合物和吡咯并嘧啶化合物在治疗由Janus激酶介导的疾病中的用途。
-
2.发明公开
公开(公告)号：EP3533796A1
公开(公告)日：2019-09-04
申请号：EP17863410.1
申请日：2017-10-27
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , HU, Yuandong , WU, Wei , DAI, Liguang , DUAN, Xiaowei , YANG, Yanqing , SUN, Yinghui , HAN, Yongxin , PENG, Yong , KONG, Fansheng , LUO, Hong , YANG, Ling , XU, Hongjiang , GUO, Meng , ZHONG, Zhaobai , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377
摘要： Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
-
公开(公告)号：EP3235819B1
公开(公告)日：2020-11-18
申请号：EP15869312.7
申请日：2015-12-15
申请人： Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
-
公开(公告)号：EP3323817A1
公开(公告)日：2018-05-23
申请号：EP16823908.5
申请日：2016-07-15
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Yan , ZHAO, Na , SHANG, Xianxing , HU, Yuandong , PENG, Yong , ZHANG, Hui , LIU, Bo , LUO, Hong , HAN, Yongxin , YANG, Ling , XU, Hongjiang
IPC分类号： C07D403/04 , C07D413/04 , A61K31/506 , A61P35/00 , A61P35/02
CPC分类号： C07D403/04 , A61K31/506 , A61K31/5377 , A61P35/00 , C07D413/04
摘要： The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases.
-
5.发明公开
公开(公告)号：EP3828183A1
公开(公告)日：2021-06-02
申请号：EP19842279.2
申请日：2019-07-25
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Shouyao Holdings (Beijing) Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： LI, Jijun , ZHU, Yan , WANG, Yeliu , SHANG, Xianxing , WANG, Huting , HE, Weinan , YAN, Qin , SUN, Yinghui , ZHANG, Kai , LU, Chang , XU, Hongjiang , TIAN, Xin , YANG, Ling
IPC分类号： C07D471/04 , C07D487/04 , A61K31/437 , A61K31/407 , A61K31/18 , A61P35/00 , A61P35/02
摘要： The present invention relates to a sulfoximine compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.
-
6.发明公开SUBSTITUTED AMINO SIX-MEMBERED SATURATED HETEROCYCLIC FAT USED AS LONG-ACTING DPP-IV INHIBITOR 审中-公开用作长效DPP-IV抑制剂的取代氨基六元饱和杂环脂
公开(公告)号：EP3257857A1
公开(公告)日：2017-12-20
申请号：EP16748717.2
申请日：2016-02-04
申请人： Centaurus BioPharma Co., Ltd. , Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： XU, Xinhe , SHEN, Yu , XIAO, Dengming , LUO, Hong , PENG, Yong , HAN, Yongxin , ZHANG, Aiming , YANG, Ling
IPC分类号： C07D513/14 , C07D487/04 , C07D495/04 , C07D405/04 , A61K31/542 , A61K31/4162 , A61K31/407 , A61K31/4035 , A61P5/50 , A61P3/10
CPC分类号： C07D513/14 , A61K31/4035 , A61K31/407 , A61K31/4162 , A61K31/542 , A61P1/00 , A61P3/04 , A61P7/00 , A61P25/00 , C07D405/04 , C07D487/04 , C07D495/04
摘要： The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition.
摘要翻译： 本申请涉及作为长效DPP-IV抑制剂的由式I表示的取代氨基六元饱和杂脂环，其制备方法，包含其的药物组合物，以及其用于治疗和 /或预防受益于DPP-IV抑制的疾病和病症。
-
公开(公告)号：EP4130042A1
公开(公告)日：2023-02-08
申请号：EP21780305.5
申请日：2021-04-01
发明人： GUI, Qiu , ZHU, Hong , WANG, Liangliang , ZHANG, Xiaoyun , ZOU, Xiaofang , SHEN, Hengqiao , XU, Hongjiang , YANG, Ling
摘要： Provided are an antigen-binding polypeptide binding to CD47 or an antigen-binding portion thereof, nucleic acids encoding the polypeptide, vector, cell or pharmaceutical composition. The polypeptide can reduce a tumor or inhibit the growth of tumor cells, treat cancer, promote macrophage phagocytosis, and the like.
-
公开(公告)号：EP3858832A1
公开(公告)日：2021-08-04
申请号：EP19878278.1
申请日：2019-10-29
发明人： LIU, Fei , FENG, Weiwei , WANG, Bin , XU, Hongjiang , WANG, Jinan , ZHANG, Xiquan , WANG, Shanchun , LIU, Yanlong , ZHANG, Jianqing , YAO, Yiyan , TANG, Xujing , SHI, Wei , ZHANG, Hongying , LI, Yang , TANG, Song , ZHU, Yizhong , LIU, Limin , GU, Hongmei , YANG, Ling
IPC分类号： C07D471/04 , C07D211/96 , C07D215/20 , A61K31/404 , A61P35/00
摘要： Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.
-
公开(公告)号：EP3248968A1
公开(公告)日：2017-11-29
申请号：EP16739808.0
申请日：2016-01-22
发明人： CHEN, Shuhui , DING, Charles Z. , YAN, Xiaobing , HUANG, Wei , HU, Guoping , LI, Jian , ZHANG, Xiquan , YANG, Ling , XU, Hongjiang
IPC分类号： C07D413/04 , C07D487/08 , C07D495/04 , C07D513/04 , C07D471/04 , C07D417/04 , C07D413/14 , A61K31/4725 , A61K31/422 , A61K31/4365 , A61K31/437
CPC分类号： C07D413/04 , A61K31/422 , A61K31/4365 , A61K31/437 , A61K31/4725 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D487/08 , C07D495/04 , C07D513/04 , Y02P20/55
摘要： The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.
摘要翻译： 本发明涉及作为HSP90抑制剂的间苯二酚衍生物或其药学上可接受的盐的式（I）所示的化合物。 本发明中的化合物具有抑制热休克蛋白HSP90的活性。 因此，本发明中的化合物用于治疗增殖性疾病如癌症和神经退行性疾病。 本发明进一步提供了用于包含所述化合物的药物组合物的化合物和制备方法，治疗疾病的方法以及包含所述化合物的药物组合物。
-
公开(公告)号：EP3865483A1
公开(公告)日：2021-08-18
申请号：EP19870704.4
申请日：2019-10-12
发明人： XU, Hongjiang , ZHANG, Mincheng , ZHANG, Ying , SONG, Wei , YANG, Ling , ZHANG, Xiquan
IPC分类号： C07D487/04 , A61P35/00 , A61K31/519
摘要： Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.03 秒)
